Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10394948" target="_blank" >RIV/00064165:_____/19:10394948 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68407700:21230/19:00331782 RIV/00216208:11110/19:10394948

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rOPI5mgVKn" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rOPI5mgVKn</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00702-019-02013-z" target="_blank" >10.1007/s00702-019-02013-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?

Popis výsledku v původním jazyce

Gait impairment is one of the common manifestations of multiple sclerosis (MS) and contributes to a loss of quality of life. Natalizumab, an anti-4 integrin monoclonal antibody, has been shown to have an effect in treatment of MS, reducing relapses and inflammatory lesions. Aim of our study was to assess how patients perceive gait impairment over the first year of treatment with natalizumab and what is the objective correlate of this change. This is an open-label prospective observational study. Subjective gait evaluation was measured by Multiple Sclerosis Walking Scale-12 (MSWS-12). Objective gait assessment included Timed 25-Foot Walk Test (T25FW) and spatiotemporal parameters of gait measured by a GAITRite instrument during a self-selected speed of walking (normal walk) and a fast speed of walking (fast walk). We analysed data of 50 patients with a relapsing-remitting form of MS, median EDSS 3.5 (range 1.5-5). MSWS-12 score significantly decreased between the baseline and month 12 of treatment (p&lt;0.001). Walking velocity and step length were significantly improved in Normal walk tests (p&lt;0.001). During the Fast walk tests, a step length and a double support time of the gait cycle were significantly improved (p=0.001). Change in MSWS-12 score confirmed the clinically significant improvement of gait in patients with MS treated with natalizumab for 1 year. The analysis of spatiotemporal gait parameters has shown a significant improvement in self-selected gait velocity and step length.

Název v anglickém jazyce

Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?

Popis výsledku anglicky

Gait impairment is one of the common manifestations of multiple sclerosis (MS) and contributes to a loss of quality of life. Natalizumab, an anti-4 integrin monoclonal antibody, has been shown to have an effect in treatment of MS, reducing relapses and inflammatory lesions. Aim of our study was to assess how patients perceive gait impairment over the first year of treatment with natalizumab and what is the objective correlate of this change. This is an open-label prospective observational study. Subjective gait evaluation was measured by Multiple Sclerosis Walking Scale-12 (MSWS-12). Objective gait assessment included Timed 25-Foot Walk Test (T25FW) and spatiotemporal parameters of gait measured by a GAITRite instrument during a self-selected speed of walking (normal walk) and a fast speed of walking (fast walk). We analysed data of 50 patients with a relapsing-remitting form of MS, median EDSS 3.5 (range 1.5-5). MSWS-12 score significantly decreased between the baseline and month 12 of treatment (p&lt;0.001). Walking velocity and step length were significantly improved in Normal walk tests (p&lt;0.001). During the Fast walk tests, a step length and a double support time of the gait cycle were significantly improved (p=0.001). Change in MSWS-12 score confirmed the clinically significant improvement of gait in patients with MS treated with natalizumab for 1 year. The analysis of spatiotemporal gait parameters has shown a significant improvement in self-selected gait velocity and step length.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neural Transmission

ISSN

0300-9564

e-ISSN

—

Svazek periodika

126

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

7

Strana od-do

731-737

Kód UT WoS článku

000469230700004

EID výsledku v databázi Scopus

2-s2.0-85066035998